Chemical Component Summary

NameZOLEDRONIC ACID
Identifiers(1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid
FormulaC5 H10 N2 O7 P2
Molecular Weight272.09
TypeNON-POLYMER
Isomeric SMILESOC(Cn1ccnc1)([P](O)(O)=O)[P](O)(O)=O
InChIInChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)
InChIKeyXRASPMIURGNCCH-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count26
Chiral Atom Count0
Bond Count26
Aromatic Bond Count5

Drug Info: DrugBank

DrugBank IDDB00399 
NameZoledronic acid
Groupsapproved
DescriptionZoledronic acid, or CGP 42'446,[A203120] is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid].[A203111] Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone.[L13712,L13715,L13721] Zoledronic acid was first described in the literature in 1994.[A203120] Zoledronic acid was granted FDA approval on 20 August 2001.[L13712]
Synonyms
  • Zoledronic Acid, Anhydrous
  • Zoledronic acid
  • ácido zoledrónico
  • Zoledronic Acid Anhydrous
  • (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
Brand Names
  • Zoledronic Acid Concentrate
  • Val-zoledronic Acid
  • Jamp-zoledronic Acid
  • Zoledronic Acid Actavis
  • Reclast
IndicationZoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women.[L13712,L13715,L13721] Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.[L13712,L13715,L13721]
Categories
  • Bisphosphonates
  • Bone Density Conservation Agents
  • Drugs Affecting Bone Structure and Mineralization
  • Drugs for Treatment of Bone Diseases
  • Imidazoles
ATC-Code
  • M05BB08
  • M05BA08
CAS number118072-93-8

Drug Targets

NameTarget SequencePharmacological ActionActions
Farnesyl pyrophosphate synthaseMPLSRWLRSVGVFLLPAPYWAPRERWLGSLRRPSLVHGYPVLAWHSARCW...unknowninhibitor
Geranylgeranyl pyrophosphate synthaseMEKTQETVQRILLEPYKYLLQLPGKQVRTKLSQAFNHWLKVPEDKLQIII...unknowninhibitor
Hydroxylapatite-unknownantagonist,binder
Multidrug resistance-associated protein 1MALRGFCSADGSDPLWDWNVTWNTSNPDFTKCFQNTVLVWVPCFYLWACF...unknownsubstrate
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682